Drugs / Mitiperstat
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT05751759 | Mar 2023 → Nov 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05457270 | Aug → Oct 2022 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05236543 | Feb → Aug 2022 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04949438 | Jan → Mar 2022 | impaired renal function disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT05052710 | Oct → Nov 2021 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04407091 | Jun → Aug 2020 | cardiovascular disorder | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04232345 | Jan 2020 → Mar 2021 | diastolic heart failure | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02712372 | Jun → Oct 2016 | cardiovascular disorder | AstraZeneca | Terminated | No outcome recorded |
| Phase 1/21 trial · 1 missed | ||||||
| Phase 1/2 | NCT03611153 | Jul 2018 → Feb 2022 | heart failure | Mayo Clinic | Completed | Missed primary |
| Phase 23 trials · 1 met primary · 2 missed | ||||||
| Phase 2 | NCT05492877 | Nov 2022 → Aug 2024 | chronic obstructive pulmonary disease | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT05638737 | Oct 2022 → Apr 2024 | metabolic dysfunction-associated steatohepatitis | AstraZeneca | Completed | Missed primary |
| Phase 2 | NCT03756285 | Dec 2018 → May 2020 | heart failure | AstraZeneca | Terminated | Met primary |
| Phase 2/31 trial · 1 missed | ||||||
| Phase 2/3 | NCT04986202 | Jun 2021 → Mar 2024 | diastolic heart failure | AstraZeneca | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT03136991 Comparator | May → Nov 2017 | cardiovascular disorder | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 17 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Mitiperstat | “Mitiperstat (AZD4831) is a novel irreversible oral myeloperoxidase inhibitor in clinical development for heart failure with preserved ejection fraction, metabolic...” PMID 39495467 ↗ Nov 20245“A Phase IIa, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability, and Pharmacodynamics of AZD4831 (Mitiperstat) in Participants With...” NCT05638737 ↗ “We tested a new drug called AZD4831 (mitiperstat), which decreases inflammation by inhibiting the enzyme myeloperoxidase.” PMID 37072105 ↗ Apr 2023 “Mitiperstat (formerly AZD4831) is a novel selective myeloperoxidase inhibitor.” PMID 37470101 ↗ Aug 2023 |
| Known as | AZD4831 | “Mitiperstat (AZD4831) is a novel irreversible oral myeloperoxidase inhibitor in clinical development for heart failure with preserved ejection fraction, metabolic...” PMID 39495467 ↗ Nov 202412“This is a research study to evaluate the efficacy and safety of the investigational drug Mitiperstat (AZD4831) in adult patients with chronic obstructive pulmonary disease.” NCT05492877 ↗ |
| Action | Inhibit | “Oral MPO inhibitor AZD4831” NCT03611153 ↗ |
| Modality | Small molecule | — CHEMBL5095218 ↗ |
| Route | Oral | “AZD4831 1-50 mg/g oral suspension” NCT02712372 ↗ |
| Target | MPO | “AZD4831 Oral Myeloperoxidase Inhibitor” NCT03611153 ↗ |